SCHEMBL23749704

SCHEMBL23749704

CN1CCP(=O)(c2ccc(Br)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
DUSP3 P51452 2/20 0.42
PTPN5 P54829 2/20 0.42
PTPN11 Q06124 2/20 0.42
POLB P06746 1/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
KMT2A Q03164 3/20 0.34
MEN1 O00255 2/20 0.34
HRH3 Q9Y5N1 2/20 0.33
HRH4 Q9H3N8 1/20 0.33
CHRNA7 P36544 1/20 0.33
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2207076 0.81 DRD1 (0.38) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL10272984 0.81 SMN1; SMN2 (0.40) ALDH1A1RAB9ANPC1LMNAMAPT
SCHEMBL16908176 0.81 MAPT (0.46) ALDH1A1LMNAKDM4EMAPTKMT2A
SCHEMBL11798652 0.80 HPGD (0.44) POLB
SCHEMBL2212046 0.79 NPSR1 (0.45) ALDH1A1POLBRAB9ANPC1NPSR1
SCHEMBL23748747 0.77 CYP2A6 (0.38) ALDH1A1RAB9ALMNANPSR1MAPT
SCHEMBL2209593 0.77 TSHR (0.41) ALDH1A1POLBNPC1KDM4EMAPT
SCHEMBL25431096 0.72 ALDH1A1 (0.52) ALDH1A1DUSP3PTPN5PTPN11NPC1
SCHEMBL2207785 0.71 DRD2 (0.43) ALDH1A1
SCHEMBL29221145 0.69 HPGD (0.42) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174565-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-08 US disclosed
US-20230174565-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2023-06-08 US disclosed
WO-2023016546-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2023-02-16 WO disclosed
WO-2023016546-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2023-02-16 WO disclosed
EP-4097099-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2022-12-07 EP disclosed
WO-2021155841-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174565-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR ALDH1A1 840/4885DUSP3 2602/4885PTPN5 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.